Patheon  (PTHN shares spiked after the provider of outsourced pharmaceutical development and manufacturing services was purchased by Thermo Fisher Scientific   (TMO - Get Report) for $7.2 billion including debt. 

Thermo Fisher's offer of $35 per share represents a 35% premium over the stock's previous closing price. The deal is expected to close by the end of the year and add 30 cents per share to Thermo Fisher's bottom line in the first year. 

Goldman Sachs  (GS - Get Report) is acting as financial adviser to Thermo Fisher in the deal and Morgan Stanley  (MS - Get Report) is acting as Patheon's financial adviser. 

Patheon shares rose 33.12% to $34.61 Monday.

Editor's note: this article has been updated since 7:53 am EST

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.